VIR
Vir Biotechnology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VIR
Vir Biotechnology, Inc.
A biotech company developing innovative treatments for infectious diseases, including hepatitis B and COVID-19
1800 Owens Street, Suite 900, San Francisco, California 94158
--
Vir Biotechnology, Inc., was incorporated under the laws of the State of Delaware on April 7, 2016. The company is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious diseases, including virus-related diseases. The company aims to achieve this in two basic ways — first, by developing powerful antibody therapies, and second, by generating unique T-cell responses in vivo through a T-cell-based viral vector platform.
Earnings Call
Q1/2025
Estimate EPS-0.84
Actual EPS-0.88
Estimate Revenue8.59M
Actual Revenue3.03M
Vir Biotechnology's Q1 2025: Unraveling Contradictions in HBV Partnerships, ECLIPSE Timelines, and T-Cell Data
May 07,2025 11:31
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.72
Actual EPS-0.8
Estimate Revenue2.72M
Actual Revenue1.21M
Vir Biotechnology’s Q2 2025: Unraveling Contradictions in ECLIPSE Trials, HDV Prevalence, and T-Cell Strategies
Aug 11,2025 06:10
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VIR has released its 2025 Q3 earnings. EPS was reported at -1.17, versus the expected -0.86, missing expectations. The chart below visualizes how VIR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VIR has released its 2025 Q3 earnings report, with revenue of 240.00K, reflecting a YoY change of -89.92%, and net profit of -163.14M, showing a YoY change of 23.66%. The Sankey diagram below clearly presents VIR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
